Marietta Wealth Management LLC Has $6.78 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Marietta Wealth Management LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,775 shares of the medical research company’s stock after selling 299 shares during the quarter. Marietta Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $6,781,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock valued at $16,582,503,000 after purchasing an additional 180,618 shares during the period. Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after purchasing an additional 50,736 shares during the period. Moneta Group Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after purchasing an additional 8,347,260 shares during the period. Providence Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after purchasing an additional 5,832,730 shares during the period. Finally, Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $3,105,677,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last ninety days. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $1.65 during trading on Tuesday, reaching $556.22. 420,584 shares of the company’s stock were exchanged, compared to its average volume of 1,531,027. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $212.31 billion, a PE ratio of 35.82, a PEG ratio of 2.38 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The firm’s fifty day moving average price is $571.79 and its 200-day moving average price is $526.53.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.40 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 10.10%.

Analyst Upgrades and Downgrades

TMO has been the subject of several recent analyst reports. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Raymond James increased their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, HSBC began coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.